About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) released its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.30. The biotechnology company had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. View Heron Therapeutics' Earnings History.

Where is Heron Therapeutics' stock going? Where will Heron Therapeutics' stock price be in 2018?

11 brokerages have issued 1-year price objectives for Heron Therapeutics' shares. Their predictions range from $22.00 to $42.00. On average, they anticipate Heron Therapeutics' share price to reach $31.18 in the next twelve months. View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

1. Cantor Fitzgerald analysts commented, "Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization." (1/15/2018)

2. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2018)

3. Mizuho analysts commented, "We analyze in greater detail Heron Therapeutics’ product HTX-011 to better understand the benefits of this extended-release combination of bupivacaine and anti-inflammatory agent meloxicam. Local anesthetics appear to lose efficacy when used in an acidic environment produced by inflammation whereas HTX-011 addresses the issue by the use of an anti-inflammation agent. We see significant upside potential if HTX-011 phase 3 readouts are positive. KeyPoints Inflammation is an unmet issue in local anesthetics. Local anesthetic failure has been observed when associated with inflammation. On page 2 and 3, we discuss two research publications to explain how inflammation can affect local anesthetics. Two theories are summarized by the authors providing evidence of reduced efficacy in generic bupivacaine when used by itself. Specifically, bupivacaine loses efficacy when used in an acidic environment produced by inflammation." (12/8/2017)

Thomas B. Ottoboni Ph.D., Senior Vice President - Pharmaceutical and Preclinical Research and Development (Age 58)

Sean T. Ristine, Vice President - Human Resources (Age 47)

Christian Waage, Director (Age 50)

Craig A. Johnson, Independent Director (Age 56)

Has Heron Therapeutics been receiving favorable news coverage?

Headlines about HRTX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heron Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Franklin Resources Inc., Wells Fargo & Company MN, Millennium Management LLC, Metropolitan Life Insurance Co. NY, TIAA CREF Investment Management LLC, Brandywine Global Investment Management LLC and Rhumbline Advisers. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart and Kimberly Manhard. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $28.90.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.39 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

MarketBeat Community Rating for Heron Therapeutics (HRTX)

MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Heron Therapeutics (NASDAQ:HRTX) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.